Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing innovative therapeutics for cancer treatment. The company was founded in 2014 and is headquartered in Wilmette, Illinois, USA. Monopar is dedicated to improving the lives of patients by developing targeted therapies that address unmet medical needs in oncology. Monopar Therapeutics is a publicly traded company and is listed on the Nasdaq stock exchange under the ticker symbol "MNPR."
The primary focus of Monopar Therapeutics is the development of antibody-drug conjugates (ADCs) and immunoconjugates. These are novel therapeutic approaches that combine the targeting ability of antibodies with the cytotoxic effects of drugs to specifically target and kill cancer cells while minimizing damage to healthy cells. Monopar's goal is to develop effective treatments for patients with difficult-to-treat cancers, including advanced solid tumors and hematological malignancies.
One of Monopar's flagship medicine is Validive® (clonidine mucobuccal tablet; MBT). Validive is a late-stage clinical product designed to reduce the severity and duration of severe oral mucositis, a common and debilitating side effect of chemotherapy and radiation therapy in cancer patients. Validive has shown promising results in clinical trials, demonstrating its potential to improve patients' quality of life during cancer treatment.
Monopar Therapeutics also collaborates with other organizations and researchers to accelerate the development of its pipeline of novel cancer therapeutics. These collaborations help leverage scientific expertise and resources to advance the company's drug candidates through preclinical and clinical stages.